Delving into the Latest Updates on Arimab USA, Inc. with Synapse

Overview

Tags

Respiratory Diseases

Infectious Diseases

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	1

Top 5 Drug Type	Count

Monoclonal antibody	1

Top 5 Target	Count

alpha-toxin(Alpha-hemolysin)	1

The main clinical efficacy objective is to evaluate the difference in clinical cure rate between SOC alone and SOC + AR-301 combination therapy on day 21. Strict clinical cure criteria have been jointly determined with clinical experts in this field; the main clinical safety objective is to evaluate the clinical safety and tolerability of AR-301 in the study population.

Start Date03 Feb 2021

Sponsor / Collaborator

Arimab USA, Inc.

[+2]

100 Clinical Results associated with Arimab USA, Inc.

Login to view more data

0 Patents (Medical) associated with Arimab USA, Inc.

Login to view more data

100 Deals associated with Arimab USA, Inc.

Login to view more data

100 Translational Medicine associated with Arimab USA, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 01 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

1

Login to view more data